Scale Events
+00:00 GMT
Sign in or Join the community to continue

Re-Engineering Drug Discovery Through ML and Digital Biology

Posted Sep 23, 2022 | Views 1.7K
Share
speakers
avatar
Jaclyn Rice Nelson
Co-founder @ Tribe AI

Jaclyn spent the majority of her career at Google partnering with enterprise companies and incubating new products. She was a founding member of the growth team at CapitalG, Alphabet’s growth equity firm, where she advised growth-stage tech companies like Airbnb and Stripe on scaling their technical infrastructure, data security, and leveraging machine learning for growth. In 2019, Jackie and Noah Gale founded Tribe AI to make AI more accessible to companies of all sizes and industries, while also building a new type of career path for top technical talent that emphasizes specialization and freedom. (Read more about it here.) Now, Tribe AI is a highly selective community of 150 machine learning engineers, researchers, and data scientists from industry leaders like Google, Tesla, and Netflix, helping companies solve their toughest business problems using ML.

+ Read More
avatar
Ben Mabey
CTO @ Recursion

Since 2020 Ben has served as chief technology officer at Recursion, a clinical-stage biotechnology company using machine learning and technological innovations to decode biology and industrialize drug discovery at scale.

Ben has over 15 years building automated ML systems and solutions in ad tech, customer service, and healthcare for companies like Savvysherpa and Red Brain Labs. Prior to becoming CTO, Ben led the Recursion engineering team and worked as a lead research data scientist.

+ Read More
SUMMARY

Using ML to decode human biology and accelerate drug discovery In the last 8 years, Recursion has built one of the largest proprietary biological data sets on earth. Every week the company runs up to 2.2 million experiments, using ML to screen biological images for disease and run simulations of potential treatments. Their vision is to decrease the rate of failure in the drug discovery process, generate novel insights to lead to better medicines, and ultimately, save the lives of patients.

Join Jaclyn Rice Nelson, CEO of Tribe AI, and Ben Mabey, CTO of Recursion, as they discuss:

How ML is driving change in drug discovery and development The Recursion approach – using biological images and deep learning to accelerate drug discovery at scale Building an applied AI company based on research Moving from IC researcher and data scientist to CTO of a public biotech company

+ Read More

Watch More

0:30
Daphne Koller: AI-Driven Drug Discovery Using Digital Biology
Posted Oct 24, 2022 | Views 1.8K
# TransformX 2022
# Keynote
# AI in Healthcare